Sonika Bhatnagar

Dr. Sonika Bhatnagar


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
AHAlejandro Hoberman
Alejandro Hoberman
NSNader Shaikh
Nader Shaikh
SBSonika Bhatnagar
Sonika Bhatnagar
MHMary Ann Haralam
Mary Ann Haralam
DKDiana H. Kearney
Diana H. Kearney
RCRussell Chesney
Russell Chesney
ImportanceA child's health, positive perceptions of the research team and consent process, and altruistic motives play significant roles in the decision-making process for parents who consent for their child to enroll in clinical research. This study identified that nonconsenting parents were better educated, had private insurance, showed lower levels of altruism, and less understanding of study design.ObjectiveTo determine the factors associated with parental consent for their child's participation in a randomized, placebo-controlled trial.DesignCross-sectional survey conducted from July 2008 to May 2011. The survey was an ancillary study to the Randomized Intervention for Children with VesicoUreteral Reflux Study.SettingSeven children's hospitals participating in a randomized trial evaluating management of children with vesicoureteral reflux.ParticipantsParents asked to provide consent for their child's participation in the randomized trial were invited to complete an anonymous online survey about factors influencing their decision. A total of 120 of the 271 (44%) invited completed the survey; 58 of 125 (46%) who had provided consent and 62 of 144 (43%) who had declined consent completed the survey.Main Outcomes and MeasuresA 60-question survey examining child, parent, and study characteristics; parental perception of the study; understanding of the design; external influences; and decision-making process.ResultsHaving graduated from college and private health insurance were associated with a lower likelihood of providing consent. Parents who perceived the trial as having a low degree of risk, resulting in greater benefit to their child and other children, causing little interference with standard care, or exhibiting potential for enhanced care, or who perceived the researcher as professional were significantly more likely to consent to participate. Higher levels of understanding of the randomization process, blinding, and right to withdraw were significantly positively associated with consent to participate.Conclusions and RelevanceParents who declined consent had a relatively higher socioeconomic status, had more anxiety about their decision, and found it harder to make their decision compared with consenting parents, who had higher levels of trust and altruism, perceived the potential for enhanced care, reflected better understanding of randomization, and exhibited low decisional uncertainty. Consideration of the factors included in the conceptual model should enhance the quality of the informed consent process and improve participation in pediatric clinical trials.

22 October 2013 in Clinical Pediatrics
Verified
Journal Article
Closed access
PDF file
SBSonika Bhatnagar
Sonika Bhatnagar
AHAlejandro Hoberman
Alejandro Hoberman
DKDiana H. Kearney
Diana H. Kearney
NSNader Shaikh
Nader Shaikh
MMMarva M. Moxey-Mims
Marva M. Moxey-Mims
AIAnastasia Ivanova
Anastasia Ivanova
Objectives. Our primary objective was to develop and evaluate an intervention to increase recruitment in a multicenter pediatric randomized clinical trial (RCT). Our secondary objective was to assess the impact beyond 120 days. Methods. The study was conducted at 17 academic centers participating in a pediatric RCT. The intervention consisted of utilizing a recruitment assessment tool at a site visit or teleconference with key site personnel. Results. We found a significant increase in the number of individuals enrolled for all 17 sites at 120 days postintervention (mean = 1.12 per site; median = 1 per site; 95% confidence interval = 1-2; P = .04). No significant differences were apparent beyond the first 120 days postintervention. Conclusions. Successful recruitment in RCTs is essential to the quality, generalizability, and cost-effectiveness of clinical research. Implementation of this recruitment intervention may effectively increase recruitment in RCTs. Beyond the first 120 days postintervention, repeated interventions may be required. What is new? Despite general and pediatric-specific challenges to recruitment in RCTs, a paucity of evidence exists on effective recruitment strategies or assessment tools to reliably enhance recruitment. We developed a recruitment intervention for use in RCTs that enables clinical researchers to enhance recruitment.

SBSonika Bhatnagar
Sonika Bhatnagar
JLJohn Lovelace
John Lovelace
RPRay Prushnok
Ray Prushnok
JKJustin Kanter
Justin Kanter
JEJoan Eichner
Joan Eichner
JSJames Schuster
James Schuster
The association between housing insecurity and reduced access to healthcare, diminished mental and physical health, and increased mortality is well-known. This association, along with structural racism, social inequities, and lack of economic opportunities, continues to widen the gap in health outcomes and other disparities between those in higher and lower socio-economic strata in the United States and throughout the advanced economies of the world. System-wide infrastructure failures at municipal, state, and federal government levels have inadequately addressed the difficulty with housing affordability and stability and its associated impact on health outcomes and inequities. Healthcare systems are uniquely poised to help fill this gap and engage with proposed solutions. Strategies that incorporate multiple investment pathways and emphasize community-based partnerships and innovation have the potential for broad public health impacts. In this manuscript, we describe a novel framework, “Give, Partner, Invest,” which was created and utilized by the University of Pittsburgh Medical Center (UPMC) Insurance Services Division (ISD) as part of the Integrated Delivery and Finance System to demonstrate the financial, policy, partnership, and workforce levers that could make substantive investments in affordable housing and community-based interventions to improve the health and well-being of our communities. Further, we address housing policy limitations and infrastructure challenges and offer potential solutions.

1 December 2021 in Pediatrics
Verified
Journal Article
Open access
GMGysella B. Muniz
Gysella B. Muniz
TSTimothy R. Shope
Timothy R. Shope
SBSonika Bhatnagar
Sonika Bhatnagar
NSNader Shaikh
Nader Shaikh
MHMary Ann Haralam
Mary Ann Haralam
AHAlejandro Hoberman
Alejandro Hoberman
BACKGROUND: Acute otitis media (AOM) is the most frequent reason for children to be prescribed antimicrobial treatment. Surfactants are naturally occurring substances that may restore the eustachian tube’s function and potentially enhance resolution of AOM. METHODS: This was a phase 2a, single-center, double-blind, randomized, placebo-controlled, parallel group clinical trial to assess safety, tolerability, and efficacy of 20 mg per day intranasal OP0201 as an adjunct therapy to oral antimicrobial agents for treating AOM in young children. We randomly assigned 103 children aged 6 to 24 months with AOM to receive either OP0201 or placebo twice daily for 10 days. All children received amoxicillin-clavulanate 90/6.4 mg/kg per day in 2 divided doses for 10 days. Participants were managed for up to 1 month. Postrandomization visits occurred between days 4 and 6 (visit 2), days 12 and 14 (visit 3), and days 26 and 30 (visit 4). Primary efficacy endpoints were resolution of a bulging tympanic membrane at visit 2 and resolution of middle-ear effusion at visit 3. RESULTS: No clinically meaningful differences between treatment groups were apparent for primary or secondary endpoints. There were no safety concerns identified. CONCLUSIONS: In young children with AOM, intranasally administered surfactant (OP0201) did not improve clinical outcomes. Further research may be warranted among children with persistent middle-ear effusion.

1 March 2020 in Clinical Trials
Verified
Journal Article
Closed access
PDF file
SBSonika Bhatnagar
Sonika Bhatnagar
AHAlejandro Hoberman
Alejandro Hoberman
MKMarcia Kurs-Lasky
Marcia Kurs-Lasky
DKDiana H Kearney
Diana H Kearney
MHMary Ann Haralam
Mary Ann Haralam
NSNader Shaikh
Nader Shaikh

1 January 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AHAlejandro Hoberman
Alejandro Hoberman
JPJack L. Paradise
Jack L. Paradise
HRHoward E. Rockette
Howard E. Rockette
JJJong-Hyeon Jeong
Jong-Hyeon Jeong
DKDiana H. Kearney
Diana H. Kearney
NSNader Shaikh
Nader Shaikh
Volume 61, no. 7, e00238-17, 2017, [https://doi.org/10.1128/AAC.00238-17][1]. Page 4: In the last row of Table 2, in the “Phase 2 children” column, the number of patients should read “(64)” instead of “(4)”. [1]: /lookup/doi/10.1128/AAC.00238-17